Medical/Pharmaceuticals
Daewoong Pharmaceutical begins the first administration of the Bersiporocin, new treatment for idiopathic pulmonary fibrosis, as Phase II clinical trial
- Evaluation of Bersiporocin's safety and efficacy against a total of 102 patients over 24 weeks - Development of treatment for pulmonary fibrosis which is unsatisfactory and in high demand, and anticipation for extended adaptability against various rare fibrosis diseases SEOUL, South Korea, Fe...
2023-02-06 13:00
1771
Gracell Biotechnologies Announces FDA Clearance of the IND Application for Phase 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Relapsed/Refractory Multiple Myeloma
BCMA/CD19 dual-targeting FasTCAR-T GC012F has demonstrated deep responses and favorable safety profile in proof of concept clinical studies Company plans to initiate Phase 1b/2 clinical trial in the U.S. in second quarter of 2023 SAN DIEGO Calif., and SUZHOU and SHANGHAI, China, Feb. 3, 2023 /PR...
2023-02-03 20:30
3910
BriSTAR Immunotech to Present at the BIO CEO & Investor Conference
BEIJING and TORONTO, Feb. 2, 2023 /PRNewswire/ -- BriSTAR Immunotech, a clinical-stage cell therapy company, announced today that its Chief Executive Officer,James Pan, Ph.D., will be presenting at the 25th BIO CEO & Investor Conference. The conference will take place at the New York Marriott Mar...
2023-02-02 19:37
2095
SONIRE Announces First Patient Enrolled in Randomized Phase 2 Study of Its Novel HIFU Therapy System for Unresectable Pancreatic Cancer Patients in Japan
TOKYO, Feb. 2, 2023 /PRNewswire/ -- SONIRE Therapeutics Inc. (hereinafter referred to as "SONIRE"), based in Tokyo, announces that it has commenced a randomized phase 2 study for the treatment of unresectable pancreatic cancer with SONIRE's next-generation High-Intensity Focused Ultrasound (HIFU)...
2023-02-02 14:00
1798
Global Times: Small and mid-sized cities in China go through infection peak, bearing new hope for future
BEIJING, Feb. 1, 2023 /PRNewswire/ -- As media sources around the world have paid so much attention to infection surges in various metropolises or first-and-second-tier cities inChina and governments at all levels have attached great importance to anti-epidemic work in rural areas, a review on ho...
2023-02-01 22:45
2286
Record short videos to assess Parkinson's disease, NERVTEX's First-in-Class AI-based Movement Dysfunction Assessment Software medical device approved
WUHAN, China, Feb. 1, 2023 /PRNewswire/ -- NERVTEX's MoDAS (Movement Dysfunction Assessment Software) system, which is a First-in-Class Artificial Intelligence/Machine Learning (AI/ML)- based Software as a Medical Device(SaMD) for the analysis of motor symptoms of Parkinson's disease and other mo...
2023-02-01 22:08
1738
HanAll Biopharma Reports Full-Year 2022 Results and Provides Business Update
* Full-Year 2022 net revenue of KRW 110 billion, up 8% over 2021 reaching a record high * Strong R&D momentum to continue with batoclimab entering multiple pivotal studies with the first Phase 3 data readout inChina expected in 2023 * Top-line data from tanfanercept's Phase 3 dry eye study e...
2023-02-01 20:00
1916
CARsgen Announces Collaboration Agreement to Evaluate AB011 in Combination with PD-L1 Checkpoint Inhibitor to Treat Gastric Cancer
SHANGHAI, Jan. 31, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative therapies for the treatment of hematologic malignancies and solid tumors, has announced CARsgen's execution of a collaboration agreement with F. Hoffmann-La Roche L...
2023-01-31 21:50
3112
Global Times: 'So much better than we had anticipated': China's rural regions embrace Spring Festival as COVID peak ebbs away
BEIJING, Jan. 31, 2023 /PRNewswire/ -- The Spring Festival is rooted in agricultural civilization. Chinese people believe the most traditional atmosphere of Spring Festival is in rural regions. Since the prevention and control of the COVID-19 epidemic has entered a new stage, questions have been...
2023-01-31 21:41
2271
Guardant Health to integrate Lunit's AI-based scoring algorithm for PD-L1 into its portfolio to enhance cancer biomarker detection
* Powered by Lunit SCOPE PD-L1, the Guardant360 TissueNext PD-L1 test with Guardant Galaxy™ shows improved detection of the biomarker in NSCLC * Lunit's AI solution is the first application in Guardant Galaxy, a suite of AI and other technology tools that enhance Guardant Health's portfolio of...
2023-01-31 21:05
2152
Zhongchao Inc. Announces Introduction of Indian Anti-influenza Drugs to China
SHANGHAI, Jan. 31, 2023 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced that that Chongqing Xinjiang Pharmaceutical Co., Ltd. ("Xinjiang...
2023-01-31 20:30
1790
Appendix 4C - Q2 FY23 Quarterly Cash Flow Report
Highlights: * Expanded participation in ATH434 Phase 2 clinical trial with sites opened for recruitment inAustralia, the United States, and Italy * Presented compelling bioMUSE data at two prestigious industry conferences * Granted a 20-year patent for 100 new compounds targeting Parkinson's...
2023-01-31 20:25
3062
Singleron to present single cell sequencing solutions at the 36th Molecular Biology of Plants Conference
COLOGNE, Germany, Jan. 31, 2023 /PRNewswire/ -- Singleron Biotechnologies
2023-01-31 16:00
2125
Oricell Publishes Data from POLARIS Clinical Study Evaluating OriCAR-017 in the Treatment of RRMM in The Lancet Haematology
SHANGHAI, Jan. 30, 2023 /PRNewswire/ -- Oricell Therapeutics Co., Ltd (Oricell), an innovative pharmaceutical company committed to the development of clinical-stage oncology cell therapies, today announced publication of data from a clinical study evaluating the efficacy of OriCAR-017, an autolog...
2023-01-31 09:24
1891
Help Therapeutics Announces IND Approval of First Universal iPSC-derived Cardiomyocyte Therapy for End-stage Heart Failure in China
BEIJING, Jan. 30, 2023 /PRNewswire/ -- Help Therapeutics Co., Ltd. (hereinafter Help Therapeutics) has revealed that the China Center for Drug Evaluation (CDE) has approved the investigational new drug (IND) application of HiCM-188, a human (allogeneic) iPS cell-derived cardiomyocyte therapy in p...
2023-01-30 23:00
2244
Health in Tech to Attend Health Care Administration Association (HCAA) Executive Forum 2023 as Corporate Sponsor
HCAA's Executive Forum 2023 is scheduled for February 20-22, 2023, at the Bellagio inLas Vegas. Be sure to stop by booth NL #9 to meet Health in Tech leadership. STUART, Fla., Jan. 30, 2023 /PRNewswire/ -- Health in Tech ("HIT", or "the Company"), an industry-leading Insurtech company that deliv...
2023-01-30 22:00
1645
Alpha Biopharma Submits New Drug Application for Zorifertinib, a Next-Generation EGFR-TKI to Treat EGFR-mutated NSCLC Patients with CNS Metastases
SHANGHAI, Jan. 29, 2023 /PRNewswire/ -- Alpha Biopharma, a developer of innovative drugs, announces that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for Zorifertinib, a next-generation EGFR-TKI specially ...
2023-01-30 10:00
2171
SK bioscience Introduces New Partnership Model to Establish Regional Vaccine Hubs
* SK bioscience shared a development history of the South Korea's first COVID-19 vaccine at the Riyadh Global Medical Biotechnology Summit 2023 (RGBMS 2023) in theKingdom of Saudi Arabia(KSA) * SK bioscience also explained a new global partnership model aiming to promote public health in deve...
2023-01-27 20:00
4066
Samsung Biologics Reports Fourth Quarter & Fiscal Year 2022 Financial Results
* Q4'22 consolidated revenue of KRW 965.5 billion and Q4'22 operating profit ofKRW 312.8 billion. * FY'22 consolidated revenue of KRW 3.00 trillion and FY'22 operating profit ofKRW 983.6 billion. * Strong growth momentum expected to continue with active expansions in capacity, geography, an...
2023-01-27 14:52
3647
Akeso Received First Tranche of US$300 Million Upfront Payment from Summit! Summit Is Accelerating Clinical Development of Ivonescimab
HONG KONG, Jan. 26, 2023 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company"), a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class and best-in-class innovative medicines globally, announced the Hart-Scott-Rodino (HSR) Act filing has c...
2023-01-26 20:24
3650
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
8288
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7685